Artisan Partners Limited Partnership purchased a new stake in Acceleron Pharma Inc. (NASDAQ:XLRN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 319,871 shares of the biopharmaceutical company’s stock, valued at approximately $11,938,000. Artisan Partners Limited Partnership owned 0.71% of Acceleron Pharma at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of XLRN. Teachers Advisors LLC grew its position in Acceleron Pharma by 2.1% in the 1st quarter. Teachers Advisors LLC now owns 46,080 shares of the biopharmaceutical company’s stock valued at $1,220,000 after purchasing an additional 942 shares during the period. Vanguard Group Inc. grew its position in Acceleron Pharma by 9.1% in the 1st quarter. Vanguard Group Inc. now owns 1,912,335 shares of the biopharmaceutical company’s stock valued at $50,619,000 after purchasing an additional 158,714 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in Acceleron Pharma by 5.9% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 131,841 shares of the biopharmaceutical company’s stock worth $3,490,000 after acquiring an additional 7,335 shares during the last quarter. NJ State Employees Deferred Compensation Plan purchased a new position in Acceleron Pharma during the 2nd quarter worth $213,000. Finally, TD Asset Management Inc. boosted its holdings in Acceleron Pharma by 0.8% during the 2nd quarter. TD Asset Management Inc. now owns 78,800 shares of the biopharmaceutical company’s stock worth $2,395,000 after acquiring an additional 600 shares during the last quarter. 85.84% of the stock is owned by institutional investors and hedge funds.

In other news, SVP Christopher Rovaldi sold 14,000 shares of the company’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $38.41, for a total transaction of $537,740.00. Following the sale, the senior vice president now directly owns 28,232 shares in the company, valued at $1,084,391.12. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP John D. Quisel sold 5,113 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $38.42, for a total value of $196,441.46. Following the sale, the senior vice president now owns 57,918 shares in the company, valued at $2,225,209.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,513 shares of company stock worth $2,055,485. Company insiders own 3.90% of the company’s stock.

Shares of Acceleron Pharma Inc. (NASDAQ XLRN) opened at $35.12 on Wednesday. Acceleron Pharma Inc. has a 52 week low of $23.07 and a 52 week high of $40.35.

Acceleron Pharma (NASDAQ:XLRN) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The business had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.52 million. During the same period in the previous year, the business posted ($0.55) EPS. The firm’s quarterly revenue was up .0% compared to the same quarter last year. analysts forecast that Acceleron Pharma Inc. will post -2.67 EPS for the current fiscal year.

A number of research firms have issued reports on XLRN. Zacks Investment Research downgraded shares of Acceleron Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Royal Bank Of Canada began coverage on shares of Acceleron Pharma in a report on Thursday, September 14th. They set a “sector perform” rating and a $44.00 price objective on the stock. Oppenheimer reaffirmed a “hold” rating on shares of Acceleron Pharma in a report on Wednesday, September 20th. Cann reaffirmed a “hold” rating on shares of Acceleron Pharma in a report on Tuesday, September 5th. Finally, ValuEngine downgraded shares of Acceleron Pharma from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $44.56.

COPYRIGHT VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/12/06/artisan-partners-limited-partnership-takes-position-in-acceleron-pharma-inc-xlrn.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc. (NASDAQ:XLRN).

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Stock Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related stocks with our FREE daily email newsletter.